Supplementary Figure S1 F-I from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

Authors:
  • JKJessica Koach
    Jessica Koach
  • JHJessica K. Holien
    Jessica K. Holien
  • HMHassina Massudi
    Hassina Massudi
  • DCDaniel R. Carter
    Daniel R. Carter
  • OCOlivia C. Ciampa
    Olivia C. Ciampa
  • MHMika Herath
    Mika Herath
  • TLTaylor Lim
    Taylor Lim
  • JSJanith A. Seneviratne
    Janith A. Seneviratne
  • GMGiorgio Milazzo
    Giorgio Milazzo
  • JMJayne E. Murray
    Jayne E. Murray
  • JMJoshua A. McCarroll
    Joshua A. McCarroll
  • BLBing Liu
    Bing Liu
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure S1. F, Confocal microscopy of SHEP Tet21N cells using anti-PA2G4 (red) and anti-MYCN (green) antibodies. G, Immunoblot analysis of cytoplasmic and nuclear fractions from BE(2)-C and Kelly human neuroblastoma cell lines with antibodies recognizing PA2G4 and MYCN, or GAPDH and topoisomerase as loading controls. H, Confocal microscopy of neuroblastoma (BE(2)-C and Kelly) cells using anti-PA2G4 (red) and anti-MYCN (green) antibodies. Alexafluor 555 anti-rabbit (to detect PA2G4) and Alexafluor 488 anti-mouse (to detect MYCN) were used as the secondary antibodies. I, Real-time PCR mRNA expression of MYCN and PA2G4 in ganglia from homozygote TH-MYCN+/+ mice, compared to wild type littermate control mice, obtained at different postnatal age (weeks).